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Summary Since the publication of the results of phase I dose-finding studies, an extensive phase 11 and III clinical study programme has been
undertaken to study the clinical efficacy and tolerability of the quinazoline folate analogue raltitrexed ('Tomudex'), a novel direct and specific
inhibitor of thymidylate synthase. Two international phase III trials, studies 3 and 12, have compared raltitrexed 3 mg m-2 with 5-fluorouracil
(5-FU) plus low-dose leucovorin (LV) (Mayo regimen) or high-dose LV (Machover regimen) respectively. A North American study (study 10)
was originally set up to compare two raltitrexed dosage arms (3.0 and 4.0 mg m-2) with 5-FU and low-dose LV, but the 4.0 mg m-2 arm was
discontinued prematurely because of excessive toxicity. Minimum follow-up times for studies 3, 10 and 12 were 15.5, 12 and 9 months,
respectively (for data other than survival), with corresponding survival follow-up times of 26, 12 and 17 months. Objective response rates
were similar for raltitrexed and 5-FU + LV, and palliative improvements were seen to a similar extent with both treatments in all phase III
studies. Survival was statistically similar for raltitrexed and 5-FU + LV in both studies 3 and 12. Raltitrexed was, however, associated with
inferior survival to 5-FU + low-dose LV in study 10, but there appears to be evidence that this was linked to an unconscious effect on
investigator behaviour of early toxicity problems in this trial, in that patients appeared to be withdrawn from raltitrexed treatment without
progression or protocolled toxicity. Moreover, it appeared that 5-FU + LV patients were continued on treatment after disease progression.
5-FU-based therapy was associated with a higher incidence of mucositis than raltitrexed in all studies, with the attainment of statistical
significance in studies 3 and 12. Elevations in hepatic transaminase levels were seen with raltitrexed, but these are thought to be of no clinical
significance. Overall, much greater levels of toxicity were seen with 5-FU + LV than with raltitrexed in early treatment cycles. In addition,
retrospective UK audit data have shown the monthly cost of raltitrexed therapy to be similar to that of Mayo and continuous infusion 5-FU
regimens, and appreciably lower than that of the de Gramont regimen of 5-FU (bolus + 22-h infusion) + high-dose LV. Thus, raltitrexed is an
effective alternative to 5-FU-based therapy in patients with advanced colorectal cancer, with an acceptable and, unlike 5-FU, predictable
toxicity profile. In particular, patients receiving raltitrexed may benefit from the minimization or avoidance of mucositis, and both patients and
healthcare providers may find the convenient administration schedule of the drug advantageous.
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Combinations of 5-fluorouracil (5-FU) and leucovorin (LV) have
been regarded for some time as standard chemotherapy for
advanced colorectal cancer (CRC) (Bleiberg, 1997). Although the
optimal treatment regimen for these two drugs has not been
unequivocally defined, the Mayo regimen of 5-FU and low-dose
LV is widely regarded as an acceptable treatment and is the only
regimen to have demonstrated a significant survival advantage over
unmodulated 5-FU (Poon et al, 1989). However, other combination
regimens, such as the Machover (5-FU with high-dose LV) regimen
(Machover et al, 1986), orcontinuously infused 5-FU (Seifert et al,
1975; Lokich et al, 1989; de Gramont et al, 1995) are also used.
Despite their widespread acceptance, combinations of5-FU and
LV require complex and inconvenient dosing schedules and are
associated with significant toxicity (Lokich et al, 1989; Poon et al,
1989; Buroker et al, 1994; Bleiberg, 1997). In view of the limita-
tions ofthese therapies, there is a need for the development ofnew
anti-cancer agents with greater or equivalent efficacy, improved
tolerability and more acceptable administration schedules.
The quinazoline folate analogue raltitrexed ('Tomudex') was
developed as part of an extensive research effort to produce a
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-direct and specific thymidylate synthase inhibitor that lacks the
non-specific effects on RNA andprotein synthesis of5-FU that are
believed to contribute to the toxicity profile ofthis drug (Jackman
and Judson, 1996; Touroutoglou and Pazdur, 1996; Bleiberg,
1997; Rustum et al, 1997). A simple dosage schedule of a single
15-min infusion once every 3 weeks is made possible with
raltitrexed by the extensive polyglutamation and subsequent reten-
tion in tissues of the drug after its uptake into cells by a reduced
folate carrier system. Phase I dose-ranging studies with raltitrexed
(Sorensen et al, 1994; Clarke et al, 1996) indicated the maximum-
tolerated doses ofthe drug to be 3.5-4.5 mg m-2.
PHASEII DATA ON RALTITREXED
In the phase II study (study 2C), conducted in 15 centres across
Europe, Australia and South Africa, 177 patients with advanced
CRC were recruited (of whom approximately 50% were patients
of the Royal Marsden Hospital). Patients who had previously
undergone chemotherapy were excluded (with the exception ofthe
5% of patients who had received prior adjuvant chemotherapy).
Raltitrexed was given at a dosage of 3 mg m-2 as a single 15-min
intravenous infusion once every 3 weeks. An overall objective
response rate (complete and partial remissions) of 26% (95% CI
'Tomudex' is a trademark, the property ofZeneca.
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Table 1 Demographic summary of studies 3,10 and 12
Study Treatment Mean age Male Colon/rectal WHO performance Prior adjuvant Measurable
(years) patients tumour status 0-1 at chemotherapy disease
(%) (%) study entry (%) (%) (%)
3 Raltitrexed 3 mg m-2 15-min infusion 61 60 59/40a 90 5 96
3-weekly
5-FU 425 mg m-2 i.v. bolus + LV 20 mgm-2 61 59 68/32 88 5 94
10 Raltitrexed 3 mg m-2 15-min infusion 61 62 79/20a 90 13 93
3-weekly
5-FU 425 mg m-2 i.v. bolus + LV 20 mg m-2 62 56 80/20 90 21 93
12 Raltitrexed 3 mg m-2 15-min infusion 60 62 65/35 90 10 94
3-weekly
5-FU 400 mg m-2 15-min infusion + LV 62 66 66/34 93 12 96
200 mg m-2
aOne site unknown. 5-FU, 5-fluorouracil; LV, leucovorin.
Table 2 Objective response rates in studies 3,10 and 12 (percentages of patients)
Response Study 3 Study 10 Study 12
Raltitrexed 5-FU+LDLV Raltitrexed 5-FU+LDLV Raltitrexed 5-FU+HDLV
(n = 223) (n = 216) (n = 199) (n = 179) (n = 230) (n = 222)
Complete (CR) 3.6 3.7 2.8 1.4 3.2 3.6
Partial (PR) 15.7 13.0 11.5 13.8 15.4 14.5
CR+PR 19.3 16.7a 14.3 15.2b 18.6 18.1c
Stable disease 35.0 32.4 33.2 40.0 51.4 52.4
ap = 0.48 between groups; bp= 0.597 between groups; cp = 0.896 between groups. 5-FU, 5-fluorouracil; LDLV, low-dose leucovorin; HDLV, high-dose leucovorin.
Table 3 Palliative benefits of chemotherapy in studies 3,10 and 12 (percentages of patients)
Parameter Study 3 Study 10 Study 12
Raltitrexed 5-FU+LDLV Raltitrexed 5-FU+LDLV Raltitrexed 5-FU+HDLV
(n = 223) (n = 216) (n = 199) (n = 179) (n= 230) (n = 222)
Weight gain .5% 16.6 15.7 21.1 27.4 13.0 18.9
Improvement in 36.4 29.7 39.1 40.8 38.2 31.1
performance status
Improvement in NA NA NA NA 86.1 83.1
disease symptoms
5-FU, 5-fluorouracil; LDLV, low-dose leucovorin; HDLV, high-dose leucovorin; NA, not available.
19-33%) was reported, which compared favourably with response
rates seen with optimally modulated 5-FU (Zalcberg et al, 1996).
Median survival was 11.2 months (95% CI 9.6-13.1 months).
PHASE III COMPARISONS OF RALTITREXED
WITH 5-FLUOROURACIL AND LEUCOVORIN IN
PATIENTS WITH ADVANCED COLORECTAL
CANCER
After these encouraging data, three prospective randomized phase
III clinical studies were set up to compare raltitrexed with modu-
lated 5-FU in patients with advanced CRC (Cunningham et al,
1996; Harper, 1997; Pazdur and Vincent, 1997). Studies 3 and 12
were conducted in Europe, South Africa and Australasia, and
study 10 in North America. In study 3 (439 patients), raltitrexed
3 mg m-2, given as a 15-min infusion once every 3 weeks, was
compared with the Mayo regimen of 5-FU (425 mg m-2 bolus)
plus low-dose LV (20 mg m-2) daily for 5 days every 4-5 weeks.
In study 12 (495 patients), the same dosage of raltitrexed was
compared with the Machover regimen of 5-FU (400 mg m-2 given
as a 15-min infusion) plus high-dose LV (200 mg m-2) daily for
5 days every 4 weeks.
A different approach was taken in the North American study 10,
in which two raltitrexed treatment arms were compared with the
Mayo regimen of5-FU plus low-dose LV. In this study, raltitrexed
was given at 3-weekly dosages of 3 and 4 mg m-2, the higher
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Figure 1 Percentages of patients categorized by response with (A) weight
improvement of at least 5% and (B) improvement in World Health
Organization (WHO) performance status (baseline performance status 2 1)
during study 3. Figures under columns denote numbers of patients. 5-FU,
5-fluorouracil; CR, complete response; PR, partial response; SD, stable
disease; LDLV, low-dose leucovorin
dosage being selected on the basis of results of one of the phase I
trials, conducted in the USA, that had suggested that raltitrexed
might be given safely at this dosage level (Sorensen et al, 1994).
These findings were in contrast to the other phase I study (which
had been carried out in the UK and the Netherlands), in which a
dosage of 3 mg m-2 was recommended for future investigations
(Clarke et al, 1996). However, the 4 mg m-2 dosage arm had to be
closed prematurely because of unacceptable toxicity, and the
subsequent intention-to-treat analysis was based on the resulting
two-arm study in 427 patients. Overall, this series of phase III
studies has provided a database of results from nearly 1500
patients, which represents a unique resource.
Maturity of data in the three studies is as follows: minimum
follow-up times for efficacy and safety for studies 3, 10 and 12 are
15.5, 12 and 9 months respectively. Corresponding times for
survival follow-up are 26, 12 and 17 months. Demographic details
for the patients enrolled are shown in Table 1 and show the treat-
ment groups to be very similar in each study. Interestingly, there
was an approximate doubling in the number of patients who had
received previous adjuvant chemotherapy in study 12 compared
with study 3. This reflects the rapid evolution ofclinical practice in
the management ofCRC that followed the publication ofnew data
on adjuvant chemotherapy between the times that these two
studies were set up (Wils, 1998).
Median durations oftherapy for each treatment group were very
similar in study 3. Patients in the raltitrexed arm were treated for a
median 15.2 weeks (five cycles), compared with 15.0 weeks (three
cycles) for patients who received 5-FU + LV. In study 12, median
duration of treatment was shorter for raltitrexed (12.7 weeks; four
cycles) than for 5-FU + LV (16.9 weeks; four cycles). However, in
study 10, there was a marked difference between median treatment
durations: 12.1 weeks (four cycles) for raltitrexed and 22.3 weeks
(five cycles) for 5-FU + LV (discussed later).
Objective response rates
Objective response was similar between treatments across all
phase III clinical trials (Table 2). The high proportion of patients
recorded as having stable disease in study 12 can be attributed to
the early first assessment (6 weeks) in this study relative to studies
3 and 10 (12 weeks), and illustrates how the changing of assess-
ment times can affect the results obtained in a clinical trial.
Table 4 Survival data from phase 11 and IlIl clinical studies of raltitrexed
Study Therapy Median survival Deaths during Hazard ratio P(between
(months) follow-up (95% Cl) treatments)
(% of patients)
2C Raltitrexed 11.2 77 NA NA
3 Raltitrexed 10.1 89 1.09 (0.89-1.33) 0.42
5-FU+LDLV 10.2 85
10 Raltitrexed 9.7 75 1.35 (1.07-1.71) 0.01
5-FU+LDLV 12.7 65
12 Raltitrexed 10.9 75 1.15 (0.93-1.42) 0.197
5-FU+HDLV 12.3 69
5-FU, 5-fluorouracil; LDLV, low-dose leucovorin; HDLV, high-dose leucovorin; NA, not applicable.
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Figure 2 Kaplan-Meier survival curves showing probability of survival over
time for raltitrexed and 5-fluorouracil (5-FU) + high-dose leucovorin (HDLV) in
phase III study 12
Palliative benefits of treatment with raltitrexed
There is an increasing appreciation ofthe importance ofthe pallia-
tive effects of treatment in patients with advanced cancer;
Redmond (1998) and Minsky (1998) have shown how the overall
effectiveness oftreatment can be enhanced by using therapies that
combine increased well-being for patients with clinical efficacy in
terms of objective response and survival. In the present phase III
clinical trials, clinically significant palliative benefits were
obtained to a similar extent with raltitrexed and 5-FU + LV in
terms of weight gain, improvements in performance status and
reductions in disease symptoms (e.g. anorexia, lethargy) (Table 3).
In study 12, more than 80% of patients with symptoms at study
entry reported improvements after treatment with either drug,
PVI 5-FU n= 141
..... Raltitrexed n = 83
- Bolus 5-FU n = 107
4 0 1 2 3
Time since treatment (years)
Figure 3 Survival in advanced colorectal cancer: prospective data collected
at the Royal Marsden hospital. Protracted intravenous infusion (PVI) of 5-
fluorouracil (5-FU) was administered at a dosage of 300 mg m-2 per day (Hill
et al, 1995a). The Wadler schedule of bolus 5-FU was used (750 mg m-2 per
day by continuous infusion for 5 days, followed by bolus 5-FU 750 mg m-2
once weekly from the start of week 2) (Hill et al, 1995b). Raltitrexed 3 mg m-2
was given by 15-min intravenous infusion every 3 weeks
which indicates the clinical significance of the quality-of-life
benefits that can be obtained with such treatments. Palliative
improvements were more frequent in patients who responded to
treatment or who had stabilization of disease than in patients
whose disease progressed (Figure 1). These data suggest that
significant clinical benefit is obtained not only in patients who
respond to chemotherapy, but also in those who achieve disease
stabilization. They also concur with observations in everyday
clinical practice that indicate that many patients feel better when
their disease is stabilized.
Raltitrexed
5-FU + LDLV (Mayo)
5-FU + HDLV (Machover)
Continuous 5-FU infusion
5-FU + HDLV (de Gramont) _
Weekly 5-FU + HDLV
5-FU alone *
Best supportive care a:e
0 1 2 3 4 5 6
4i
I
I -
_ _l .I
_
,
-- .t - l -
7 8 9 10 11 12 13 14 15 16 17 18 19
Median survival (months)
Figure 4 Pooled survival data from 43 clinical studies in patients with advanced colorectal cancer. 5-FU, 5-fluorouracil; HDLV, high-dose leucovorin; LDLV,
low-dose leucovorin
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Table 5 WHO grade 3 or 4 adverse events that were observed in at least 5% of patients in studies 3, 10 and 12
Adverse event Study 3 Study 10 Study 12
Raltitrexed 5-FU+LDLV Raltitrexed 5-FU+LDLV Raltitrexed 5-FU+HDLV
(n = 223) (n = 216) (n = 199) (n = 179) (n = 230) (n = 222)
Leucopenia 14 30a 18 41 a 6 13
Mucositis (stomatitis) 2 22a 3 10 2 16a
Anaemia 9a 2 9 4 5 2
Elevated transaminases 1Oa 0 7 1 13a 9
Nausea/vomiting 13 9 13 8 9 9
Asthenia (severe) 6 2 18 10 5 2
Diarrhoea 14 14 10 13 10 19
Thrombocytopenia 4 1 5 3 3 0
Infection 5 5 6 7 4 3
Pain 5 7 14 16 5 4
ap< 0.001 (Holm's procedure).
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Figure 5 Percentages of patients with WHO grade 3 or 4 adverse events
who required dosage reduction in study 3. 5-FU, 5-fluorouracil; LDLV, low-
dose leucovorin
Survival
Survival is a key end point in randomized clinical studies of anti-
cancer agents, and data are available for all such studies conducted
to date with raltitrexed (Table 4). The median survival of 11.2
months obtained in the phase II trial was ofthe order expected in a
patient sample of the type recruited, and data from the first phase
III study (study 3) showed the survival curves forraltitrexed and 5-
FU + LV to be superimposable. Survival data from study 10 (North
American) showed a significantly shorter survival with raltitrexed
than with the Mayo regimen of 5-FU + LV (Table 4). It is thought
that this was attributable to the much longer duration oftreatment
of5-FU + LV patients, which itselfappears to be a consequence of
unconscious investigator bias. Data indicate that patients were
withdrawn early from raltitrexed treatment without apparently
meeting the protocol requirements for progression or toxicity, and
that proportionately more 5-FU + LV patients were continued on
treatment after disease progression. These behaviours probably
stem from the termination of the 4 mg m-2 raltitrexed arm in this
trial because ofunacceptable toxicity, coupled with the familiarity
of the investigators with the 5-FU + LV regimen. There was no
statistically significant difference between treatments in study 12
(illustrated in Figure 2). Non-randomized prospective phase II data
collected at the Royal Marsden Hospital also show comparability
ofsurvival with raltitrexed and different 5-FU regimens (Figure 3).
An analysis of 43 prospective, randomized, peer-reviewed
clinical studies of chemotherapy in advanced CRC (published in
English-language journals since 1991, in addition to key studies
published before this date) has shown consistency of survival
results across phase II and III trials of raltitrexed compared with
those obtained with other regimens. These disparities are illus-
trated in Figure 4 and may be attributed to variable study condi-
tions at different centres or to differences in patient selection
criteria and/or methods. In particular, there is a wide variation
across the literature in survival results with the de Gramont
5-FU + high-dose LVregimen. Notably, however, there are evident
advantages relative to best supportive care alone in the use of
chemotherapy in advanced CRC: median survival times with
raltitrexed, for example, are approximately twice those seen with
best supportive care alone.
ADVERSE EVENTS IN PHASE III STUDIES
A summary of WHO grade 3 and 4 adverse events that were
recorded in at least 5% ofpatients in the phase III studies is given
in Table 5. Higher frequencies of mucositis were seen with 5-FU-
based regimens in all trials, with statistical significance being
attained in studies 3 and 12. Higher frequencies of disturbance of
hepatic enzymes were seen with raltitrexed (7-13%). However,
many antimetabolites (e.g. methotrexate) are associated with tran-
sient and reversible increases in hepatic transaminase levels that
are not thought to have any clinical significance. The incidence of
mucositis was lower for both treatments in study 10; this may be
attributable to the more widespread use of 'ice-chip' therapy (i.e.
the retention ofcrushed ice cubes in the mouth) in the USA. 5-FU
+ LV was also associated with a significantly higher incidence of
leucopenia in studies 3 and 10 (with a trend towards a higher inci-
dence in study 12). Otherwise, tolerability ofraltitrexed and 5-FU-
based therapy was broadly similar across all studies. Examination
ofthe incidence ofWHO grade 3 or 4 adverse events by treatment
cycle revealed that early treatment cycles were associated with
much greater toxicity with 5-FU + LV than with raltitrexed. This
high incidence of toxicity decreased with each cycle until the
incidence of grade 3-4 adverse events was statistically similar
between treatment groups from cycle 4 onwards (Figure 5). High
early levels oftoxicity in patients receiving 5-FU + LV are associ-
ated with the variation across populations in the ability ofpatients
to metabolize this drug. Variable activity of the degradative
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Figure 7 Effect of mucositis on parameters of patient well-being during the
first 4 weeks of adjuvant treatment with 5-fluorouracil + low-dose leucovorin
(Mayo regimen) (Asserohn et al, submitted). Patients scored the severity of a
symptom or loss of function on a visual analogue scale of 0-100. A mean
score for the group was calculated at the end of each week
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Figure 6 Percentages of patients who required dosage reductions in all
phase IlIl studies. 5-FU, 5-fluorouracil; LV, leucovorin
enzyme dihydropyrimfiidine dehydrogenase (DPD) makes the
selection of the correct dosage of5-FU for each individual patient
difficult, and dosage reductions are often required early in treat-
ment to correct the severe toxicity that may be initially encoun-
tered. Figure 6 illustrates the much greater need for early dosage
reductions with 5-FU-based treatment than with raltitrexed across
all three phase III studies and reflects the more reliable and
predictable toxicity profile ofraltitrexed.
Mucositis
Mucositis is an important dose-limiting adverse effect associated
with regimens based on 5-FU and LV. Mucositis reaches grade 3-4
Mayo Raltitrexed Continuous de
5-FU infusion Gramont
Regimen
Figure 8 Mean monthly total treatment costs of various chemotherapy
regimens in patients with advanced colorectal cancer: results from a
retrospective audit of 116 patients (Ross et al, 1996b)
severity in 22-36% of patients (Ross et al, 1996a), may lead to
Gram-negative infection and/or hospitalization, and is potentially
life-threatening. A study has therefore been carried out at the
Royal Marsden Hospital to address the problems of underestima-
tion of the impact of this adverse effect on patients and its under-
reporting in clinical studies (Assersohn et al, submitted). The
effect of mucositis on quality of life and well-being in patients
receiving the Mayo regimen of5-FU and low-dose LV as adjuvant
therapy was measured on a weekly basis in this study, with docu-
mentation by a nurse specialist of levels of discomfort and diffi-
-culty in speaking, chewing and sleeping experienced by patients.
The most severe clinical sequelae ofmucositis were seen during
the first 3 weeks of therapy (it should be noted that these patients
were generally clinically well before chemotherapy), with particu-
larly severe impairment of quality of life across weeks 1 and 2
(Figure 7). A major contributor to this was the loss ofthe ability of
patients to tolerate solid foods. At week4, arapidreturn to baseline
symptom scores was recorded. Thus, mucositis adversely affects
quality of life to a considerable extent, and further investigation is
required to increase our understanding of its pathophysiology and
to minimize its incidence and its effect on patient well-being.
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COST OF TREATMENT WITH RALTITREXED AND
OTHER CHEMOTHERAPY REGIMENS
Favourable cost-of-treatment data for 3-weekly administration of
raltitrexed 3 mg m-2 have been reported by Ross et al (1996b) in a
retrospective audit of 116 sets of notes from patients with
advanced CRC. As shown in Figure 8, when all hospital compo-
nents oftreatment were accounted for (with the exclusion ofphar-
macy resources), the monthly cost ofraltitrexed was considerably
lower than that of the de Gramont regimen (5-FU 400 mg m-2
bolus + LV 200 mg m-2 2-h infusion, followed by 22-h infusion of
5-FU 400 mg m-2 for 2 days every 2 weeks) (de Gramont et al,
1995) and similar to those of the Mayo regimen (bolus 5-FU
425 mg m-2 + low-dose LV 20 mg m-2 for 5 days every 4-5 weeks)
(Poon et al, 1989) and a continuous ambulatory infusional regimen
(5-FU 300 mg m-2 per day). Total costs were as follows: Mayo
regimen £954.03 (mean) and £659.68 (median); raltitrexed
£1117.85 (mean) and £959.34 (median); continuous ambulatory 5-
FU £1207.61 (mean) and £749.19 (median); and de Gramont
£2028.52 (mean) and £1775.66 (median). The pattern of costs
varied considerably between regimens, such that high drug acqui-
sition costs (e.g. as with raltitrexed) were offset by reductions in
the number and cost ofhospital visits and stays.
CONCLUSIONS
Overall, the results of this landmark series of studies show that
objective response rates and palliative benefits were equivalent for
raltitrexed and regimens based on 5-FU and LV in patients with
advanced CRC. The toxicity of raltitrexed is acceptable, consis-
tent, manageable and, unlike that with 5-FU + LV, predictable.
Work carried out at the Royal Marsden Hospital has given an
indication of the full deleterious effect on patient well-being of
mucositis, and patients may benefit from the minimization or
avoidance of this adverse effect by the use of raltitrexed. In addi-
tion, the convenient administration schedule of this drug reduces
the burden placed by treatment on patients and their families and
healthcare providers. Available data show that the overall monthly
cost of using raltitrexed is no greater than that incurred with the
Mayo regimen or continuous ambulatory 5-FU, and is consider-
ably less than that with the de Gramont regimen.
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